REVB
Revelation Biosciences, Inc. (REVB) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (D+). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B+ (3.7) | C+ (2.8) | D+ (1.5) | C- (2.0) | C+ (2.6) | C+ (2.5) |
| 2026-11-07 | B+ (3.8) | C+ (2.7) | C+ (2.5) | C- (2.0) | C+ (2.7) | C+ (2.7) |
| 2026-10-31 | B+ (3.8) | C+ (2.6) | C+ (2.6) | D+ (1.8) | C+ (2.7) | C+ (2.7) |
| 2026-10-24 | B+ (3.7) | C+ (2.6) | C+ (2.5) | C (2.4) | C+ (2.6) | C+ (2.8) |
| 2026-10-17 | B+ (3.7) | C+ (2.6) | C+ (2.5) | D (1.2) | C+ (2.6) | C+ (2.5) |